Evidence map›Paper›PMID 27884751›Full record

SynthesisNeuroscience and biobehavioral reviews2017

A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.

Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Green

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neuroscience and biobehavioral reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Acute effects of ΔPsychopharmacology · 2022
    Trial
  6. A randomised controlled trial of vaporised ΔEuropean archives of psychiatry and clinical neuroscience · 2019
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ashleigh L OsborneCentre for Translational Neuroscience, Illawarra Health and Medical Research Institute, University of Wollongong, 2522, NSW, Australia; Illawarra Health and Medical Research Institute, University of Wollongong, 2522, NSW, Australia; Centre for Medical and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, 2522, NSW, Australia.
Nadia SolowijSchool of Psychology, Faculty of Social Sciences, University of Wollongong, 2522, NSW, Australia; Illawarra Health and Medical Research Institute, University of Wollongong, 2522, NSW, Australia.
Katrina Weston-GreenCentre for Translational Neuroscience, Illawarra Health and Medical Research Institute, University of Wollongong, 2522, NSW, Australia; Illawarra Health and Medical Research Institute, University of Wollongong, 2522, NSW, Australia; Centre for Medical and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, 2522, NSW, Australia. Electronic address: katrina_green@uow.edu.au.
Illawarra Health and Medical Research Institute · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesCognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored. The aim of this systematic review was to evaluate preclinical and clinical literature on the effects of CBD in cognitive domains relevant to schizophrenia.

methodsA systematic literature search was performed across numerous electronic databases for English language articles (January 1990-March 2016), with 27 articles (18 preclinical and 9 clinical studies) included in the present review.

resultsCBD improves cognition in multiple preclinical models of cognitive impairment, including models of neuropsychiatric (schizophrenia), neurodegenerative (Alzheimer's disease), neuro-inflammatory (meningitis, sepsis and cerebral malaria) and neurological disorders (hepatic encephalopathy and brain ischemia). To date, there is one clinical investigation into the effects of CBD on cognition in schizophrenia patients, with negative results for the Stroop test. CBD attenuates Δ

conclusionsThe efficacy of CBD to improve cognition in schizophrenia cannot be elucidated due to lack of clinical evidence; however, given the ability of CBD to restore cognition in multiple studies of impairment, further investigation into its efficacy in schizophrenia is warranted. Potential mechanisms underlying the efficacy of CBD to improve cognition are discussed.

Indexed as

CognitionSchizophreniaAntipsychotic AgentsCannabidiolDronabinolHumansAntipsychotic AgentsCannabidiolDronabinolAlzheimer’s diseaseAntipsychotic drugsBrain ischemiaCannabidiolCannabisCerebral malariaCognitionCognitive impairmentCognitive testingHepatic encephalopathyMeningitisNeurodegenerationNeuro-inflammationNeuropsychiatricSchizophreniaSepsisΔ9-Tetrahydrocannabinol

Identifiers

PMID27884751
OpenAlexW2551555892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.